McKesson Corporation (MCK) Gross Margin: 3.61%
Is McKesson Corporation’s gross margin high or low?
McKesson Corporation's gross margin of 3.61% is 13% below its 5-year average of 4.16%, near the low end of its 5-year range (3.48%–4.86%).
As of Friday, June 19, 2026. 1.83% above its 12-month average of 3.54%.
MCK Gross Margin Chart
MCK Average Gross Margin Chart
MCK Current vs Average Gross Margin Chart
MCK Gross Margin Metrics
GROSS MARGIN
3.61%
GROSS MARGIN AVG TTM
3.54%
GROSS MARGIN AVG 3Y
3.83%
GROSS MARGIN AVG 5Y
4.16%
GROSS MARGIN AVG 10Y
4.64%
GROSS MARGIN AVG 15Y
5.04%
GROSS MARGIN AVG 20Y
5.06%
CURRENT VS TTM AVG
+1.83%
CURRENT VS 3Y AVG
-5.81%
CURRENT VS 5Y AVG
-13.29%
CURRENT VS 10Y AVG
-22.18%
CURRENT VS 15Y AVG
-28.36%
CURRENT VS 20Y AVG
-28.65%
MCK Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| McKesson Corporation (MCK) | $87.88B | 3.61% | 3.54% | 3.83% | 4.16% |
| Elevance Health Inc. (ELV)vs › | $84.37B | 23.16% | 26.70% | 26.59% | 26.68% |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | 34.92% | 41.06% | 39.99% | 47.00% |
| Medtronic plc (MDT)vs › | $101.86B | 65.02% | 65.17% | 65.34% | 65.75% |
| Cigna Corporation (CI)vs › | $73.88B | 9.30% | 9.98% | 11.47% | 12.36% |
| Boston Scientific Corporation (BSX)vs › | $67.35B | 70.41% | 65.16% | 63.29% | 62.03% |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | 68.75% | 62.23% | 59.55% | 57.82% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | 84.55% | 85.74% | 85.09% | 84.57% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | 86.28% | 85.57% | 86.56% | 87.08% |
| Stryker Corporation (SYK)vs › | $119.03B | 63.67% | 62.91% | 61.66% | 61.70% |
Gross Margin Analysis
Gross Margin
3.6%
(Revenue - COGS) / Revenue
McKesson Corporation Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation Gross Margin FAQ
- What is the gross margin for McKesson Corporation (MCK)?
- The gross margin for MCK stock is 3.61%.
- Is McKesson Corporation's gross margin high or low?
- McKesson Corporation's gross margin of 3.61% is 13% below its 5-year average of 4.16%, near the low end of its 5-year range (3.48%–4.86%).
- What is the TTM average gross margin for McKesson Corporation (MCK)?
- The TTM average gross margin for MCK stock is 3.54%.
- What is the 3Y average gross margin for McKesson Corporation (MCK)?
- The 3Y average gross margin for MCK stock is 3.83%.
- What is the 5Y average gross margin for McKesson Corporation (MCK)?
- The 5Y average gross margin for MCK stock is 4.16%.
- What is the 10Y average gross margin for McKesson Corporation (MCK)?
- The 10Y average gross margin for MCK stock is 4.64%.
- What is the 15Y average gross margin for McKesson Corporation (MCK)?
- The 15Y average gross margin for MCK stock is 5.04%.
- What is the 20Y average gross margin for McKesson Corporation (MCK)?
- The 20Y average gross margin for MCK stock is 5.06%.
McKesson Corporation Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 3.61% |
| 2025-03-31 | 3.48% |
| 2024-03-31 | 3.95% |
| 2023-03-31 | 4.29% |
| 2022-03-31 | 4.79% |
| 2021-03-31 | 4.86% |
| 2020-03-31 | 4.93% |
| 2019-03-31 | 5.02% |
| 2018-03-31 | 4.99% |
| 2017-03-31 | 5.38% |
| 2016-03-31 | 5.73% |
| 2015-03-31 | 6.10% |
| 2014-03-31 | 5.84% |
| 2013-03-31 | 5.51% |
| 2012-03-31 | 5.24% |
| 2011-03-31 | 5.35% |
| 2010-03-31 | 5.23% |
| 2009-03-31 | 5.05% |
| 2008-03-31 | 4.92% |
| 2007-03-31 | 4.66% |
| 2006-03-31 | 4.29% |
| 2005-03-31 | 4.28% |
| 2004-03-31 | 4.67% |
| 2003-03-31 | 5.43% |
| 2002-03-31 | 5.59% |
| 2001-03-31 | 5.79% |
| 2000-03-31 | 6.87% |
| 1999-03-31 | 9.43% |
| 1998-03-31 | 7.71% |
| 1997-03-31 | 8.61% |
Related Metrics
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler